Filing Overview
Issuer: I-MAB, a foreign private issuer headquartered in Shanghai, China. The request metadata identifies Novabridge Biosciences, but the filing text identifies the registrant as I-MAB.
Form and period: Form 6-K covering the month of November 2021, furnished on November 12, 2021. The filing references unaudited condensed consolidated interim financial statements, related discussion, and updated risk factors in Exhibits 99.1, 99.2, and 99.3; the exhibit contents were not included in the provided text.
Financial Information
- Revenue, profit, cash flow, and margins: The provided filing text does not include financial statement amounts or operating metrics.
- Debt and liquidity: The provided filing text does not provide clear debt, cash, liquidity, or financing values.
- Other financial metrics: The filing identifies Exhibit 99.1 as containing unaudited interim financial statements, but those statements are not included in the source text.
Material Changes and Commentary
The filing text does not describe specific changes versus the prior comparable period, management commentary, guidance, outlook, unusual items, contingencies, or financial results. These matters may be addressed in Exhibits 99.1 and 99.2, which were referenced but not provided.
Risk Factors and Filing Mechanics
- Exhibit 99.3 is identified as containing updated risk factors; the specific risks are not included in the provided text.
- Exhibits 99.1, 99.2, and 99.3 are incorporated by reference into I-MAB’s Form F-3 registration statement, File No. 333-252793, to the extent not superseded by subsequent filings.
- I-MAB indicated that it files or will file annual reports on Form 20-F rather than Form 40-F.
Investor Verification Checklist
- Obtain and review Exhibit 99.1 for revenue, net loss, cash flow, cash balances, debt, and liquidity.
- Review Exhibit 99.2 for period-over-period changes, management explanations, and outlook or guidance.
- Review Exhibit 99.3 for newly identified or updated clinical, regulatory, financing, operational, and other risks.
- Confirm the registrant identity, because the supplied metadata names Novabridge Biosciences while the filing names I-MAB.